Description: Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Home Page: www.newron.com
Via Antonio Meucci 3
Bresso,
MI
20091
Italy
Phone:
39 02 610 3461
Officers
| Name | Title |
|---|---|
| Mr. Stefan Weber | CEO & Executive Director |
| Mr. Roberto Galli | Chief Financial Officer |
| Mr. Filippo Moriggia | Vice President of Operations |
| Dr. Ravi Anand M.D., Ph.D. | Chief Medical Officer |
| Ms. Laura Faravelli | Vice President of Business Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 12.1507 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 22.6532 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |